CN103736014A - Chinese medicinal composition for treating prostatic hyperplasia - Google Patents
Chinese medicinal composition for treating prostatic hyperplasia Download PDFInfo
- Publication number
- CN103736014A CN103736014A CN201310742679.7A CN201310742679A CN103736014A CN 103736014 A CN103736014 A CN 103736014A CN 201310742679 A CN201310742679 A CN 201310742679A CN 103736014 A CN103736014 A CN 103736014A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- chinese medicinal
- medicinal composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese medicinal composition for treating prostatic hyperplasia. The Chinese medicinal composition consists of the following components in parts by weight: 30-40 parts of acanthopanax root, 30-40 parts of medicinal indianmulberry root, 30-40 parts of mantis egg-case, 30-40 parts of human placenta, 30-40 parts of Chinese yam, 20-30 parts of cowherb seed, 20-30 parts of large-head atractylodes rhizome, 20-30 parts of bamboo leaf, 20-30 parts of heartleaf houttuynia herb, 20-30 parts of ramie root, 10-20 parts of Rubia cordifolia L., 10-20 parts of curcuma zedoary, 10-20 parts of corydalis tuber and 10-20 parts of motherwort herb. The Chinese medicinal composition for treating prostatic hyperplasia is prepared according to the theory of traditional Chinese medicine, and has the effects of tonifying qi, invigorating the kidneys, strengthening yang, dredging the meridian, inducing diuresis, promoting blood circulation and promoting the circulation of qi. The Chinese medicinal preparation is less in toxic and side effects and low in cost, and can be used for treating both symptoms and root causes.
Description
Technical field
The present invention relates to field of traditional Chinese, particularly a kind of Chinese medicine composition for the treatment of hyperplasia of prostate.
Background technology
Prostatic hyperplasia (BPH) is one of male senile patient common disease, cumulative many with population in the world senescence onset of illness.The sickness rate of prostatic hyperplasia increased progressively with the age, but not necessarily had clinical symptoms while having preneoplastic lesions.
Hyperplasia of prostate is relevant with the traditional Chinese medical science " difficulty in urination ".The name of " difficulty in urination ", first sees < < Huang di's Canon of Medicine > >.As this defeated > > piece of writing of < < Huang di's Canon of Medicine Ling Shu Miraculous Pivot or Divine Axis is said: " difficulty in urination, void is incontinence of urine." < < Huang di's Canon of Medicine Plain Questions declares five gas piece of writing > > and also says: " bladder discord, for infirmity, is not about incontinence of urine." traditional Chinese medical science thinks, worn with age, kidney qi virtual loss is the pathogenesis basis of primary disease, and it is basic pathological factor that blood stasis loses essence, and excessive fatigue, the stimulation of feelings will, diseases caused by exogenous pathogenic factor six climate exopathogens, eating and drinking without temperance are common onset conditions, and deficiency in origin and excess in superficiality is the basic pathogenesis feature of primary disease.Only hyperplasia of prostate and the difficulty in urination these two, the former is with its pathological change speech, the latter is with its dysuria speech, the angle difference of name.
The medicine of existing this type of disease for the treatment of is a lot, the general conventional medicines such as " QIANLIEKANG ", " QIANLIETONG JIAONANG " that adopt, although these conventional medicines have certain therapeutic effect, existence is cured the symptoms, not the disease, curative effect is slow, the course for the treatment of is long, cure rate is low and the shortcoming of easy recurrence.Doctor trained in Western medicine is the modern so-called high-tech laser surgery therapy of many employings, and this is a kind of wound therapy, can cause infection, to patient, brings unnecessary trouble.
Summary of the invention
For the defect existing in prior art, the object of the present invention is to provide a kind of Chinese medicine composition for the treatment of hyperplasia of prostate.
Technical scheme of the present invention is as follows:
Treat a Chinese medicine composition for hyperplasia of prostate, by following component, according to weight fraction, formed:
Radix Et Caulis Acanthopanacis Senticosi 30-40 part, Radix Morindae Officinalis 30-40 part, Ootheca Mantidis 30-40 part, Placenta Hominis 30-40 part, Rhizoma Dioscoreae 30-40 part, Semen Vaccariae 20-30 part, Rhizoma Atractylodis Macrocephalae 20-30 part, Folium Bambusae 20-30 part, Herba Houttuyniae 20-30 part, Radix Boehmeriae 20-30 part, Radix Rubiae 10-20 part, Rhizoma Curcumae 10-20 part, Rhizoma Corydalis 10-20 part, Herba Leonuri 10-20 part.
On the basis of such scheme, a kind of Chinese medicine composition for the treatment of hyperplasia of prostate, is comprised of according to weight fraction following component:
35 parts of Radix Et Caulis Acanthopanacis Senticosis, 35 parts of Radix Morindae Officinaliss, 35 parts of Ootheca Mantidiss, 35 parts of Placenta Hominiss, 35 parts of Rhizoma Dioscoreaes, 25 parts of Semen Vaccariae, 25 parts of the Rhizoma Atractylodis Macrocephalaes, 25 parts, Folium Bambusae, 25 parts of Herba Houttuyniae, 25 parts of Radix Boehmeriaes, 15 parts, Radix Rubiae, 15 parts of Rhizoma Curcumae, 15 parts of Rhizoma Corydalis, 15 parts of Herba Leonuris.
Chinese medicine composition of the present invention, reasonable recipe, in prescription: Radix Et Caulis Acanthopanacis Senticosi replenishing QI to invigorate the spleen, tonifying the kidney for tranquilization, Radix Morindae Officinalis reinforcing the kidney and supporting YANG, Ootheca Mantidis reinforcing the kidney and supporting YANG, controlling nocturnal emission with astringent drugs reducing urination, Placenta Hominis is mended essence, is nourished blood, QI invigorating, Rhizoma Dioscoreae supplementing QI and nourishing YIN, Chinese medicine of the five flavours is monarch drug altogether; Semen Vaccariae is invigorated blood circulation, is stimulated the menstrual flow, and Rhizoma Atractylodis Macrocephalae air making-up and spleen enlivening, dampness diuretic, promote the production of body fluid at Folium Bambusae diuresis, Herba Houttuyniae heat-clearing and toxic substances removing, inducing diuresis for treating stranguria syndrome, and Radix Boehmeriae diuresis, removing toxic substances, Chinese medicine of the five flavours is ministerial drug altogether; Radix Rubiae cooling blood for hemostasis, blood circulation promoting and blood stasis dispelling, Rhizoma Curcumae promoting the circulation of QI to relieve pain, removing blood stasis, Rhizoma Corydalis blood-activating and qi-promoting, pain relieving, Herba Leonuri blood circulation promoting and blood stasis dispelling, inducing diuresis to remove edema, heat-clearing and toxic substances removing, four taste Chinese medicines are adjuvant drug altogether; 14 taste Chinese medicines share, play altogether QI invigorating, kidney invigorating and YANG supporting, stimulate the menstrual flow, diuresis, invigorate blood circulation, the effect of circulation of qi promoting, effectively treat hyperplasia of prostate.
The Chinese medicine composition for the treatment of hyperplasia of prostate of the present invention, formulated according to theory of Chinese medical science, QI invigorating, kidney invigorating and YANG supporting, stimulate the menstrual flow, diuresis, invigorate blood circulation, circulation of qi promoting, Chinese medicine preparation, toxic and side effects is little, cost is low, treating both the principal and secondary aspects of a disease.
The specific embodiment
Embodiment 1
Treat a Chinese medicine composition for hyperplasia of prostate, by following component, according to weight fraction, form (every part of 1g):
30 parts of Radix Et Caulis Acanthopanacis Senticosis, 30 parts of Radix Morindae Officinaliss, 30 parts of Ootheca Mantidiss, 30 parts of Placenta Hominiss, 30 parts of Rhizoma Dioscoreaes, 20 parts of Semen Vaccariae, 20 parts of the Rhizoma Atractylodis Macrocephalaes, 20 parts, Folium Bambusae, 20 parts of Herba Houttuyniae, 20 parts of Radix Boehmeriaes, 10 parts, Radix Rubiae, 10 parts of Rhizoma Curcumae, 10 parts of Rhizoma Corydalis, 10 parts of Herba Leonuris.
Embodiment 2
Treat a Chinese medicine composition for hyperplasia of prostate, by following component, according to weight fraction, form (every part of 1g):
35 parts of Radix Et Caulis Acanthopanacis Senticosis, 35 parts of Radix Morindae Officinaliss, 35 parts of Ootheca Mantidiss, 35 parts of Placenta Hominiss, 35 parts of Rhizoma Dioscoreaes, 25 parts of Semen Vaccariae, 25 parts of the Rhizoma Atractylodis Macrocephalaes, 25 parts, Folium Bambusae, 25 parts of Herba Houttuyniae, 25 parts of Radix Boehmeriaes, 15 parts, Radix Rubiae, 15 parts of Rhizoma Curcumae, 15 parts of Rhizoma Corydalis, 15 parts of Herba Leonuris.
Embodiment 3
Treat a Chinese medicine composition for hyperplasia of prostate, by following component, according to weight fraction, form (every part of 1g):
40 parts of Radix Et Caulis Acanthopanacis Senticosis, 40 parts of Radix Morindae Officinaliss, 40 parts of Ootheca Mantidiss, 40 parts of Placenta Hominiss, 40 parts of Rhizoma Dioscoreaes, 30 parts of Semen Vaccariae, 30 parts of the Rhizoma Atractylodis Macrocephalaes, 30 parts, Folium Bambusae, 30 parts of Herba Houttuyniae, 30 parts of Radix Boehmeriaes, 20 parts, Radix Rubiae, 20 parts of Rhizoma Curcumae, 20 parts of Rhizoma Corydalis, 20 parts of Herba Leonuris.
Experimental example:
The present invention treats the prescription of hyperplasia of prostate and makes traditionally decoction, every day potion, be a course for the treatment of at twice, 30 day every day, takes continuously 3 courses for the treatment of.
The present invention chooses 80 routine benign prostatic hyperplasia patientss altogether.In 80 routine patients, 40 years old of age minimum, maximum 85 years old, 54 years old mean age, the course of disease 3~10 years.
Curative effect judging standard is:
Cure: after treatment, the transference cures such as pudendum discomfort, pain, burning sensation, semen in urine, seminal emission and frequent micturition, dysuria, do not affect sleep and orthobiosis.Nothing recurrence in 3 years.
Take a turn for the better: after treatment, the symptoms such as pudendum discomfort, pain, burning sensation, semen in urine, seminal emission and frequent micturition, dysuria, obviously alleviate and take a turn for the better.
Invalid: after treatment, the symptoms such as pudendum discomfort, pain, burning sensation, semen in urine, seminal emission and frequent micturition, dysuria, are not improved or increase the weight of.
80 routine patients take the medicine of embodiment 2, after the treatment of 3 courses for the treatment of, cure 68 examples, 12 examples that take a turn for the better, invalid 0 example.
Claims (2)
1. treat a Chinese medicine composition for hyperplasia of prostate, it is characterized in that being formed according to weight fraction by following component:
Radix Et Caulis Acanthopanacis Senticosi 30-40 part, Radix Morindae Officinalis 30-40 part, Ootheca Mantidis 30-40 part, Placenta Hominis 30-40 part, Rhizoma Dioscoreae 30-40 part, Semen Vaccariae 20-30 part, Rhizoma Atractylodis Macrocephalae 20-30 part, Folium Bambusae 20-30 part, Herba Houttuyniae 20-30 part, Radix Boehmeriae 20-30 part, Radix Rubiae 10-20 part, Rhizoma Curcumae 10-20 part, Rhizoma Corydalis 10-20 part, Herba Leonuri 10-20 part.
2. the Chinese medicine composition for the treatment of hyperplasia of prostate according to claim 1, is characterized in that being comprised of according to weight fraction following component:
35 parts of Radix Et Caulis Acanthopanacis Senticosis, 35 parts of Radix Morindae Officinaliss, 35 parts of Ootheca Mantidiss, 35 parts of Placenta Hominiss, 35 parts of Rhizoma Dioscoreaes, 25 parts of Semen Vaccariae, 25 parts of the Rhizoma Atractylodis Macrocephalaes, 25 parts, Folium Bambusae, 25 parts of Herba Houttuyniae, 25 parts of Radix Boehmeriaes, 15 parts, Radix Rubiae, 15 parts of Rhizoma Curcumae, 15 parts of Rhizoma Corydalis, 15 parts of Herba Leonuris.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310742679.7A CN103736014B (en) | 2013-12-27 | 2013-12-27 | A kind of Chinese medicine composition for the treatment of hyperplasia of prostate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310742679.7A CN103736014B (en) | 2013-12-27 | 2013-12-27 | A kind of Chinese medicine composition for the treatment of hyperplasia of prostate |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103736014A true CN103736014A (en) | 2014-04-23 |
CN103736014B CN103736014B (en) | 2016-03-30 |
Family
ID=50493130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310742679.7A Expired - Fee Related CN103736014B (en) | 2013-12-27 | 2013-12-27 | A kind of Chinese medicine composition for the treatment of hyperplasia of prostate |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103736014B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103721193A (en) * | 2014-01-02 | 2014-04-16 | 张永雷 | Traditional Chinese medicine composition for treating prostate hyperplasia |
CN105902847A (en) * | 2016-04-24 | 2016-08-31 | 邹洪胜 | Traditional Chinese medicinal composition for treating prostatoplasia |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101732660A (en) * | 2009-12-25 | 2010-06-16 | 卢速江 | Chinese medicinal preparation for treating prostate disease and preparation method thereof |
-
2013
- 2013-12-27 CN CN201310742679.7A patent/CN103736014B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101732660A (en) * | 2009-12-25 | 2010-06-16 | 卢速江 | Chinese medicinal preparation for treating prostate disease and preparation method thereof |
Non-Patent Citations (4)
Title |
---|
于月书等: "王久源教授从脏腑论治前列腺增生", 《河南中医》 * |
詹慧春等: "中医药治疗前列腺增生症的临床研究概况", 《实用中西医结合临床》 * |
韦景春: "前列腺增生症中医药治疗概述", 《实用中医内科杂志》 * |
黄飞等: "中药复方治疗前列腺增生症概况", 《中医杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103721193A (en) * | 2014-01-02 | 2014-04-16 | 张永雷 | Traditional Chinese medicine composition for treating prostate hyperplasia |
CN105902847A (en) * | 2016-04-24 | 2016-08-31 | 邹洪胜 | Traditional Chinese medicinal composition for treating prostatoplasia |
Also Published As
Publication number | Publication date |
---|---|
CN103736014B (en) | 2016-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101411802B (en) | Black plaster for treating hyperosteogeny and preparation method thereof | |
CN100548350C (en) | A kind of Chinese medicine for the treatment of thromboangiitis obliterans | |
CN104208483A (en) | Traditional Chinese medicine composition for treating anaphylactic rhinitis | |
CN101647878B (en) | Traditional Chinese medicine preparation for treating rheumatism and numbness | |
CN101396541B (en) | Traditional Chinese medicine for treating the cervical vertebra disease | |
CN102335265A (en) | Chinese medicament for treating psoriasis | |
CN103736014B (en) | A kind of Chinese medicine composition for the treatment of hyperplasia of prostate | |
CN102716334A (en) | Chinese medicinal composition for dispelling the cold and removing stasis | |
CN100546640C (en) | A kind of Chinese medicine composition of orally taken for curing cyclomastopathy | |
CN103720762A (en) | Fumigant for treating rhinitis and preparation method thereof | |
CN104740142A (en) | Traditional Chinese medicine for treating sciatica | |
CN102370853A (en) | Traditional Chinese medicine for treating chronic pyelonephritis | |
CN108210551A (en) | A kind of Chinese medicine composition and its preparation method and application and application process | |
CN104771516A (en) | Traditional Chinese medicine composition for treating allergic dermatitis | |
CN101129718B (en) | Traditional Chinese medicine preparation for treating leuoderma | |
CN104398949A (en) | Traditional Chinese medicine oral liquid for treating prostatitis | |
CN104288604B (en) | A kind of Chinese medicine composition for treating cerebral infarction | |
CN103721193A (en) | Traditional Chinese medicine composition for treating prostate hyperplasia | |
CN102198201B (en) | Traditional Chinese medicine composition for treating deficiency-cold headache | |
CN101983712A (en) | Novel medicament for treating coronary heart disease | |
CN106511574A (en) | Traditional Chinese medicine externally applied plaster for treating wind-cold-dampness syndrome cervical spondylosis | |
CN101693095A (en) | Traditional Chinese medicine preparation for treating cirrhosis and liver ascites | |
CN105998559A (en) | Traditional Chinese medicine composition for treating Parkinson's disease | |
CN106110217A (en) | A kind of medicated wine for treating cervical spondylosis | |
CN106038806A (en) | Traditional Chinese medicine composition for treating leucoderma and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160330 Termination date: 20161227 |
|
CF01 | Termination of patent right due to non-payment of annual fee |